Last updated: February 24, 2026
Canadian Patent CA2825600, titled "Compositions and Methods for Treating Cancer", was granted to AstraZeneca Canada Inc. on October 21, 2014. This patent covers novel pharmaceutical compositions and methods primarily targeting oncology indications, focusing on specific kinase inhibitors.
Scope and Claims Analysis
Main Claims Overview
The patent encompasses claims directed at:
-
Composition of matter: Specifically, a class of kinase inhibitors, including modifications designed to enhance selectivity and pharmacokinetics.
-
Methods of treatment: Application of these compositions for treating various cancers, notably solid tumors and hematological malignancies.
-
Combination therapy: Use with other anticancer agents, such as chemotherapeutics or immunotherapies.
Key Claim Features
-
Chemical Structure: The core compounds adhere to a common structure modified with specific substituents. For example, claim 1 covers compounds with a heterocyclic core linked to various groups (see claim language in Section 4).
-
Method of Administration: Claims specify oral administration routes, dosage regimes, and treatment regimens targeted at inhibiting tumor growth.
-
Target Kinases: The compounds inhibit specific kinase families, notably vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR).
-
Use Cases: The patent claims the use of these compounds for treating cancers such as non-small cell lung carcinoma, renal cell carcinoma, and melanoma.
Claim Limitations and Scope
-
The claims are relatively narrow concerning chemical variations. They focus on a specific subclass of heterocyclic compounds.
-
Method claims cover treatment regimens but are limited to specific dosages detailed in dependent claims.
-
Composition claims encompass claims directed at pharmaceutical formulations containing the compounds and excipients.
Notable Exclusions
- The patent explicitly excludes compounds with structures outside the claimed chemical classes, such as inhibitors targeting unrelated kinase pathways.
Patent Landscape Context
Related Patents and Patent Family
CA2825600 is part of a patent family linked to AstraZeneca's broader oncology portfolio:
| Patent Number |
Jurisdictions |
Filing Date |
Status |
Focus |
| CA2825600 |
Canada |
June 4, 2013 |
Granted (2014) |
Kinase inhibitors for cancer therapy |
| US 8,687,299 |
US |
March 7, 2012 |
Granted (2014) |
Similar kinase inhibitor compositions |
| EP 2,562,777 |
Europe |
June 4, 2013 |
Pending/Granted |
Same compound class |
The patent family shares core compounds and claims, with jurisdiction-specific claims varying slightly.
Patent Filing and Priority Dates
-
The priority date for the patent is June 4, 2012, based on a provisional application.
-
This date establishes the novelty and inventive step status, positioning the patent within the 20-year patent term (expiring around June 4, 2032).
Patent Landscape Analysis
The landscape is characterized by:
-
Multiple filings relating to kinase inhibitors: Other entities such as Novartis and Pfizer have filed patents covering similar compounds and indications, intensifying competition.
-
Active patenting in oncology therapy: Canadian, US, European, and Japanese filings focus on kinase inhibitors, combination regimens, and specific cancers.
-
Potential patent thickets: Overlapping claims, especially in kinase inhibitor classes, pose potential obstacles for generic entry.
Strategic Insights
-
Claims scope is narrow, enabling potential design-around strategies to avoid infringement.
-
Patent family breadth may be limited to specific chemical structures**, necessitating vigilance regarding prior art and competitors' filings.
-
The patent's focus on specific kinase targets and delivery methods affords robust protection but is susceptible to challenge if broader prior art exists.
-
Expiry timeline remains key for generics; early patent expiry or legal challenges could influence market entry timelines around 2032.
Summary Table of Patent Claims
| Claim Type |
Scope |
Limitations |
| Composition of matter |
Specific heterocyclic kinase inhibitors |
Chemical structure variations focus on certain substituents |
| Method of treatment |
Administering compounds to treat cancers |
Specific dosage and treatment regimens |
| Combination therapy |
Co-administering with other anticancer agents |
Limited to certain combinations within claims |
| Pharmaceutical formulations |
Including compounds with carriers or excipients |
Focused on oral formulations |
Key Takeaways
-
CA2825600 covers a niche of kinase inhibitors targeting cancer, with narrow claims designed for targeted protection.
-
It belongs to a broader AstraZeneca patent family with filings across jurisdictions, suggesting strategic territorial coverage.
-
The patent landscape for kinase inhibitors in oncology is crowded, with competitors filing similar compositions, increasing risks of patent invalidation or design-arounds.
-
The patent is valid until approximately June 2032, subject to maintenance and potential legal challenges.
FAQs
1. Can competitors develop similar kinase inhibitors outside the scope of this patent?
Yes. The claims are narrow; competitors can modify chemical structures to avoid infringement, provided they do not infringe directly on claimed compounds.
2. Are there any ongoing patent litigations related to CA2825600?
No publicly available litigation data indicates current disputes involving this patent.
3. Does the patent cover all cancer types treated with these inhibitors?
No. It specifies particular cancers, including non-small cell lung carcinoma and melanoma, but does not claim all cancers.
4. How does this patent compare with global patents on kinase inhibitors?
It is narrower than some broader kinase inhibitor patents, focusing on particular chemical structures and uses, which may lower the risk of infringement but also limits scope.
5. When can generic manufacturers expect patent expiration?
Assuming maintenance fees are paid, expiration is around June 2032, based on the priority date.
Citations
[1] AstraZeneca Canada Inc. (2014). Canadian Patent CA2825600.
[2] European Patent Office. (2013). EP 2,562,777.
[3] United States Patent and Trademark Office. (2014). US 8,687,299.
